NovaBridge Biosciences (NBP)
Nasdaq · Healthcare · Biotechnology
$1.36+0.37%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $158M
- 52-week range
- $1.31 – $6.79
- 52-week change
- −68.99%
- EPS (trailing)
- −$0.69
Fiscal year to Dec 2025
- Net income
- −$46.3M
- Diluted EPS
- −$0.21
From the company’s annual report on SEC EDGAR.
About NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab.
Headquarters: Rockville, United States · 30 employees · novabridge.com